These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 33645009)

  • 21. MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes.
    Li Y; Guessous F; Zhang Y; Dipierro C; Kefas B; Johnson E; Marcinkiewicz L; Jiang J; Yang Y; Schmittgen TD; Lopes B; Schiff D; Purow B; Abounader R
    Cancer Res; 2009 Oct; 69(19):7569-76. PubMed ID: 19773441
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of a novel KLC1-ROS1 fusion in a case of pediatric low-grade localized glioma.
    Nakano Y; Tomiyama A; Kohno T; Yoshida A; Yamasaki K; Ozawa T; Fukuoka K; Fukushima H; Inoue T; Hara J; Sakamoto H; Ichimura K
    Brain Tumor Pathol; 2019 Jan; 36(1):14-19. PubMed ID: 30350109
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Missense mutation of the MET gene detected in human glioma.
    Moon YW; Weil RJ; Pack SD; Park WS; Pak E; Pham T; Karkera JD; Kim HK; Vortmeyer AO; Fuller BG; Zhuang Z
    Mod Pathol; 2000 Sep; 13(9):973-7. PubMed ID: 11007037
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aberrant methylation and silencing of the SPINT2 gene in high-grade gliomas.
    Fukushima T; Kawaguchi M; Yamamoto K; Yamashita F; Izumi A; Kaieda T; Takezaki Y; Itoh H; Takeshima H; Kataoka H
    Cancer Sci; 2018 Sep; 109(9):2970-2979. PubMed ID: 29987920
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An orally bioavailable c-Met kinase inhibitor potently inhibits brain tumor malignancy and growth.
    Guessous F; Zhang Y; diPierro C; Marcinkiewicz L; Sarkaria J; Schiff D; Buchanan S; Abounader R
    Anticancer Agents Med Chem; 2010 Jan; 10(1):28-35. PubMed ID: 20015006
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of a novel MET mutation in high-grade glioma resulting in an auto-active intracellular protein.
    Navis AC; van Lith SA; van Duijnhoven SM; de Pooter M; Yetkin-Arik B; Wesseling P; Hendriks WJ; Venselaar H; Timmer M; van Cleef P; van Bergen En Henegouwen P; Best MG; Wurdinger TD; Tops BB; Leenders WP
    Acta Neuropathol; 2015 Jul; 130(1):131-44. PubMed ID: 25862637
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Negative control of the HGF/c-MET pathway by TGF-β: a new look at the regulation of stemness in glioblastoma.
    Papa E; Weller M; Weiss T; Ventura E; Burghardt I; Szabó E
    Cell Death Dis; 2017 Dec; 8(12):3210. PubMed ID: 29238047
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MET overexpression contributes to STAT4-PD-L1 signaling activation associated with tumor-associated, macrophages-mediated immunosuppression in primary glioblastomas.
    Wang QW; Sun LH; Zhang Y; Wang Z; Zhao Z; Wang ZL; Wang KY; Li GZ; Xu JB; Ren CY; Ma WP; Wang HJ; Li SW; Zhu YJ; Jiang T; Bao ZS
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34667077
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma.
    Parker BC; Annala MJ; Cogdell DE; Granberg KJ; Sun Y; Ji P; Li X; Gumin J; Zheng H; Hu L; Yli-Harja O; Haapasalo H; Visakorpi T; Liu X; Liu CG; Sawaya R; Fuller GN; Chen K; Lang FF; Nykter M; Zhang W
    J Clin Invest; 2013 Feb; 123(2):855-65. PubMed ID: 23298836
    [TBL] [Abstract][Full Text] [Related]  

  • 30. C-MET overexpression and amplification in gliomas.
    Kwak Y; Kim SI; Park CK; Paek SH; Lee ST; Park SH
    Int J Clin Exp Pathol; 2015; 8(11):14932-8. PubMed ID: 26823824
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nuclear FABP7 immunoreactivity is preferentially expressed in infiltrative glioma and is associated with poor prognosis in EGFR-overexpressing glioblastoma.
    Liang Y; Bollen AW; Aldape KD; Gupta N
    BMC Cancer; 2006 Apr; 6():97. PubMed ID: 16623952
    [TBL] [Abstract][Full Text] [Related]  

  • 32. C-Met antisense oligodeoxynucleotide inhibits growth of glioma cells.
    Chu S; Yuan X; Li Z; Jiang P; Zhang J
    Surg Neurol; 2006 Jun; 65(6):533-8; discussion 538. PubMed ID: 16720163
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intracellular and extracellular domains of protein tyrosine phosphatase PTPRZ-B differentially regulate glioma cell growth and motility.
    Bourgonje AM; Navis AC; Schepens JT; Verrijp K; Hovestad L; Hilhorst R; Harroch S; Wesseling P; Leenders WP; Hendriks WJ
    Oncotarget; 2014 Sep; 5(18):8690-702. PubMed ID: 25238264
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ACTC1 as an invasion and prognosis marker in glioma.
    Ohtaki S; Wanibuchi M; Kataoka-Sasaki Y; Sasaki M; Oka S; Noshiro S; Akiyama Y; Mikami T; Mikuni N; Kocsis JD; Honmou O
    J Neurosurg; 2017 Feb; 126(2):467-475. PubMed ID: 27081897
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comprehensive protein tyrosine phosphatase mRNA profiling identifies new regulators in the progression of glioma.
    Bourgonje AM; Verrijp K; Schepens JT; Navis AC; Piepers JA; Palmen CB; van den Eijnden M; Hooft van Huijsduijnen R; Wesseling P; Leenders WP; Hendriks WJ
    Acta Neuropathol Commun; 2016 Sep; 4(1):96. PubMed ID: 27586084
    [TBL] [Abstract][Full Text] [Related]  

  • 36. GOPC-ROS1 Fusion Due to Microdeletion at 6q22 Is an Oncogenic Driver in a Subset of Pediatric Gliomas and Glioneuronal Tumors.
    Richardson TE; Tang K; Vasudevaraja V; Serrano J; William CM; Mirchia K; Pierson CR; Leonard JR; AbdelBaki MS; Schieffer KM; Cottrell CE; Tovar-Spinoza Z; Comito MA; Boué DR; Jour G; Snuderl M
    J Neuropathol Exp Neurol; 2019 Dec; 78(12):1089-1099. PubMed ID: 31626289
    [TBL] [Abstract][Full Text] [Related]  

  • 37. LncRNA LINC00998 inhibits the malignant glioma phenotype via the CBX3-mediated c-Met/Akt/mTOR axis.
    Cai H; Yu Y; Ni X; Li C; Hu Y; Wang J; Chen F; Xi S; Chen Z
    Cell Death Dis; 2020 Dec; 11(12):1032. PubMed ID: 33268783
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The human Fn14 receptor gene is up-regulated in migrating glioma cells in vitro and overexpressed in advanced glial tumors.
    Tran NL; McDonough WS; Donohue PJ; Winkles JA; Berens TJ; Ross KR; Hoelzinger DB; Beaudry C; Coons SW; Berens ME
    Am J Pathol; 2003 Apr; 162(4):1313-21. PubMed ID: 12651623
    [TBL] [Abstract][Full Text] [Related]  

  • 39. c-Met antisense oligodeoxynucleotides as a novel therapeutic agent for glioma: in vitro and in vivo studies of uptake, effects, and toxicity.
    Chu SH; Zhang H; Ma YB; Feng DF; Zhu ZA; Yuan XH; Li ZQ
    J Surg Res; 2007 Aug; 141(2):284-8. PubMed ID: 17561117
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PTEN reconstitution alters glioma responses to c-Met pathway inhibition.
    Goodwin CR; Lal B; Ho S; Woodard CL; Zhou X; Taeger A; Xia S; Laterra J
    Anticancer Drugs; 2011 Oct; 22(9):905-12. PubMed ID: 21654317
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.